Pharmaceutical heavyweight Mylan, the latest poster child for drug-industry greed, finally stuck up for itself Thursday. It argued that “the system,” not avarice, was to blame for the company jacking up the price of EpiPens, a common (and life-saving) allergy remedy, by over 400%.
“Look, no one’s more frustrated than me,” Mylan Chief Executive Heather Bresch declared on CNBC.
03:00 Carrier incentives stir debate over 'rewarding' offshoring8
16:38 Swift Energy completes $40 million sale of Louisiana asset9
21:23 Princess Cruises to pay record-breaking criminal fine for ocean pollution13
20:05 Essential Politics: Pelosi wins another term as Democratic leader, Sanders warns against 'liberal elite'16